DiNonA Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Employees
-
22
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$143M
- Investors
-
1
DiNonA General Information
Description
Developer of an antibody drug therapeutics based in Seoul, South Korea. The company specializes in researching and developing antibody related therapeutics and diagnostic reagents.
Contact Information
Website
www.dinonainc.comCorporate Office
- Asan institute for Life Sciences
- 11th Floor, 88, Olympic-ro 43-gil Songpa-gu
- Seoul
- South Korea
Corporate Office
- Asan institute for Life Sciences
- 11th Floor, 88, Olympic-ro 43-gil Songpa-gu
- Seoul
- South Korea
DiNonA Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 27-Oct-2021 | $143M | Completed | Generating Revenue | ||
| 5. PIPE | 30-Oct-2020 | Completed | Generating Revenue | |||
| 4. PIPE | 31-Jul-2020 | Completed | Generating Revenue | |||
| 3. IPO | 08-May-2018 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 01-Jan-2015 | $3.62M | $4.51M | Completed | Startup | |
| 1. Later Stage VC | 01-Mar-2012 | $890K | $890K | Completed | Startup |
DiNonA Patents
DiNonA Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2022518363-A | Antibodies that specifically bind to icam-1 and their uses | Active | 31-Dec-2018 | ||
| WO-2020141869-A1 | Antibody specifically binding to icam-1 and use thereof | Inactive | 31-Dec-2018 | ||
| JP-2021523193-A | Prophylactic and therapeutic uses for bone marrow-derived inhibitory cell-related diseases | Active | 14-May-2018 | ||
| CA-3099968-A1 | Use for preventing and treating myeloid-derived suppressor cell-related diseases | Inactive | 14-May-2018 | ||
| WO-2019221574-A1 | Use for preventing and treating myeloid-derived suppressor cell-related diseases | Inactive | 14-May-2018 | A61K40/42 |
DiNonA Signals
DiNonA Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DSC Investment | Venture Capital | Minority | ||
| HB Investment | Venture Capital | Minority | ||
| ID Ventures (South Korea) | Venture Capital | Minority | ||
| IMM Investment | Asset Manager | Minority | ||
| InterVest | Venture Capital | Minority |
DiNonA Investments (2)
DiNonA’s most recent deal was a PIPE with Hwail Pharmaceutical for . The deal was made on 29-Sep-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Hwail Pharmaceutical | 29-Sep-2020 | PIPE | Other Pharmaceuticals and Biotechnology | ||
| Hwail Pharmaceutical | 18-Sep-2020 | Secondary Transaction - Private | Other Pharmaceuticals and Biotechnology |
DiNonA FAQs
-
When was DiNonA founded?
DiNonA was founded in 1999.
-
Where is DiNonA headquartered?
DiNonA is headquartered in Seoul, South Korea.
-
What is the size of DiNonA?
DiNonA has 22 total employees.
-
What industry is DiNonA in?
DiNonA’s primary industry is Biotechnology.
-
Is DiNonA a private or public company?
DiNonA is a Private company.
-
What is the current valuation of DiNonA?
The current valuation of DiNonA is .
-
What is DiNonA’s current revenue?
The current revenue for DiNonA is .
-
How much funding has DiNonA raised over time?
DiNonA has raised $7.9M.
-
Who are DiNonA’s investors?
DSC Investment, HB Investment, ID Ventures (South Korea), IMM Investment, and InterVest are 5 of 7 investors who have invested in DiNonA.
-
When was DiNonA acquired?
DiNonA was acquired on 27-Oct-2021.
-
Who acquired DiNonA?
DiNonA was acquired by Ecovolt (South Korea) and Kumho HT.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process